In the SURMOUNT 2 trial,20 tirzepatide 15 mg—a dual agonist acting on both GLP‐1 and glucose‐dependent insulinotropic polypeptide (GIP) receptors—led to 14.7% mean WL in people with T2D and overweight/obesity vs. 3.2% WL with placebo after 72 weeks of treatment; moreover, 79% of participants achieved HbA1c ≤6.5% with tirzepatide 15 mg compared to 20% with placebo. Here, GLP1R is linked to obesity disorder.